RxDoctor Payments Data

Steven Stein, MD

Psychiatry · Sarasota, FLNPI 1417319104

Payments from drug & device makers

$1,641in general payments, 2019–2025

Across 58 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$448
  • Otsuka America Pharmaceutical, Inc.$194
  • AbbVie$136
  • Alkermes, Inc.$135
  • Supernus Pharmaceuticals, Inc.$134
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
  • plus $507 from 13 others

What the payments were for

  • Food & beverage$1,641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,641 in reported general payments places this provider in the 65th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$110,465
Medicare patients
105
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$24,030
Lurasidone Hcl25$19,753
Aripiprazole28$2,065
Bupropion XlBupropion Hcl60$1,334
Trazodone Hcl67$1,154
Quetiapine Fumarate42$1,027
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$996
Escitalopram Oxalate72$856
Lamotrigine69$799
Buspirone Hcl43$626
Sertraline Hcl78$409
Duloxetine Hcl16$372
Bupropion Hcl SrBupropion Hcl42$343
Clonazepam16$302
Mirtazapine28$284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$194$24,03017 claims
Almatica Pharma LLCSertraline Hcl$18$40978 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →